Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options

SIMPLE SUMMARY: Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is currently indicated as first-line therapy in patients with non-small-cell lung cancer (NSCLC) and sensitizing EGFR mutations; as second-line therapy in patients who present the resis...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomatou, Georgia, Syrigos, Nikolaos, Kotteas, Elias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913144/
https://www.ncbi.nlm.nih.gov/pubmed/36765799
http://dx.doi.org/10.3390/cancers15030841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913144/
https://www.ncbi.nlm.nih.gov/pubmed/36765799
http://dx.doi.org/10.3390/cancers15030841

Ejemplares similares